Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 1.14.11.7 - procollagen-proline 3-dioxygenase

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Acidosis
Acidosis induces antimicrobial peptide expression and resistance to uropathogenic E. coli infection in kidney collecting duct cells via HIF-1?.
Antioxidants, HIF prolyl hydroxylase inhibitors or short interfering RNAs to BNIP3 or PUMA, can prevent prodeath effects of the transcriptional activator, HIF-1alpha, in a mouse hippocampal neuronal line.
Acidosis, Lactic
Targeting Oxygen-Sensing Prolyl Hydroxylase for Metformin-Associated Lactic Acidosis Treatment.
Acute Lung Injury
Bleomycin-induced pulmonary fibrosis in the rat. Prevention with an inhibitor of collagen synthesis.
Alzheimer Disease
Biological implications of the interaction (via silanol groups) of silicon with metal ions.
Amyloidosis
Differential expression of MAP3K7 and TROPONIN C proteins and related perturbations in renal amyloidosis.
Anemia
1,3,8-Triazaspiro[4.5]decane-2,4-diones as Efficacious Pan-Inhibitors of Hypoxia-Inducible Factor Prolyl Hydroxylase 1-3 (HIF PHD1-3) for the Treatment of Anemia.
A Randomized, Placebo- and Positive-Controlled, Single-Dose, Crossover Thorough QT/QTc Study Assessing the Effect of Daprodustat on Cardiac Repolarization in Healthy Subjects.
Anemia in chronic kidney disease.
Anemia in conventional hemodialysis: Finding the optimal treatment balance.
Click Chemistry-Based Discovery of [3-Hydroxy-5-(1 H-1,2,3-triazol-4-yl)picolinoyl]glycines as Orally Active Hypoxia-Inducing Factor Prolyl Hydroxylase Inhibitors with Favorable Safety Profiles for the Treatment of Anemia.
Discovery of Clinical Candidate (5-(3-(4-Chlorophenoxy)prop-1-yn-1-yl)-3-hydroxypicolinoyl)glycine, an Orally Bioavailable Prolyl Hydroxylase Inhibitor for the Treatment of Anemia.
Discovery of JTZ-951: A HIF Prolyl Hydroxylase Inhibitor for the Treatment of Renal Anemia.
Discovery of novel 2-[(4-hydroxy-6-oxo-2,3-dihydro-1H-pyridine-5-carbonyl)amino]acetic acid derivatives as HIF prolyl hydroxylase inhibitors for treatment of renal anemia.
DMOG, a Prolyl Hydroxylase Inhibitor, Increases Hemoglobin Levels without Exacerbating Hypertension and Renal Injury in Salt-Sensitive Hypertensive Rats.
Effectiveness of hypoxia-induced factor prolyl hydroxylase inhibitor for managing anemia in chronic kidney disease: a systematic review and meta-analysis.
Effects of orally active hypoxia inducible factor alpha prolyl hydroxylase inhibitor, FG4592 on renal fibrogenic potential in mouse unilateral ureteral obstruction model.
Efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) on anemia in non-dialysis-dependent chronic kidney disease (NDD-CKD): a systematic review and meta-analysis.
Erratum Regarding "Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors: A Potential New Treatment for Anemia in Patients With CKD" (Am J Kidney Dis. 2017;69[6]:815-826).
Erythropoietin regulation of red blood cell production: from bench to bedside and back.
Expanding roles of the hypoxia-response network in chronic kidney disease.
Giving Anemia a Boost with Inhibitors of Prolyl Hydroxylase.
HIF stabilization by prolyl hydroxylase inhibitors for the treatment of anemia in chronic kidney disease.
How I treat cancer-associated anemia.
Hypoxia signaling in renal pericytes-is it safe to activate?
Hypoxia-inducible factor activation in diabetic kidney disease.
Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors: A Potential New Treatment for Anemia in Patients With CKD.
Hypoxia-Inducible Factor Stabilization as an Emerging Therapy for CKD-Related Anemia: Report From a Scientific Workshop Sponsored by the National Kidney Foundation.
Influence of acute and chronic kidney failure in rats on the disposition and pharmacokinetics of ZYAN1, a novel prolyl hydroxylase inhibitor, for the treatment of chronic kidney disease-induced anemia.
Inhibition of oxygen-sensing prolyl hydroxylases increases lipid accumulation in human primary tubular epithelial cells without inducing ER stress.
lmplementation of the prolyl hydroxylase inhibitor Roxadustat (FG-4592) and its main metabolites into routine doping controls.
New renal anemia drugs: is there really anything new on the horizon?
Pharmacologic Targeting of Hypoxia-Inducible Factors.
Pharmacological Characterization of ZYAN1, a Novel Prolyl Hydroxylase Inhibitor for the Treatment of Anemia.
Pharmacological inhibition of prolyl hydroxylase protects against inflammation-induced anemia via efficient erythropoiesis and hepcidin downregulation.
Physiology and pathophysiology of renal erythropoietin-producing cells.
Prolyl hydroxylase domain-2 (PHD2) inhibition may be a better therapeutic strategy in renal anemia.
Prolyl hydroxylase domain-containing protein inhibitors as stabilizers of hypoxia-inducible factor: small molecule-based therapeutics for anemia.
Prolyl hydroxylase inhibition corrects functional iron deficiency and inflammation-induced anaemia in rats.
Prolyl hydroxylase inhibition protects the kidneys from ischemia via upregulation of glycogen storage.
Prolyl hydroxylase inhibitor desidustat protects against acute and chronic kidney injury by reducing inflammatory cytokines and oxidative stress.
Prolyl Hydroxylase Inhibitors: A Breakthrough in the Therapy of Anemia Associated with Chronic Diseases.
Protein Hydroxylation by Hypoxia-Inducible Factor (HIF) Hydroxylases: Unique or Ubiquitous?
Roxadustat attenuates experimental pulmonary fibrosis in vitro and in vivo.
Roxadustat Markedly Reduces Myocardial Ischemia Reperfusion Injury in Mice.
Roxadustat: First Global Approval.
Study design and baseline characteristics of patients on dialysis in the ASCEND-D trial.
The efficacy and safety of roxadustat treatment for anemia in patients with kidney disease: a meta-analysis and systematic review.
The HIF-PHI BAY 85-3934 (Molidustat) improves anemia and is associated with reduced levels of circulating FGF23 in a CKD mouse model.
The latest advances in kidney diseases and related disorders.
The oral hypoxia-inducible factor prolyl hydroxylase inhibitor enarodustat counteracts alterations in renal energy metabolism in the early stages of diabetic kidney disease.
The prolyl hydroxylase inhibitor roxadustat: Paradigm in drug discovery and prospects for clinical application beyond anemia.
Vadadustat: First Approval.
Whether Prolyl Hydroxylase Blocker-Roxadustat-In the Treatment of Anemia in Patients with Chronic Kidney Disease Is the Future?
Anemia, Sickle Cell
Serum enzymes of collagen synthesis and type III procollagen amino-propeptide in Nigerian patients with sickle cell disease.
Angiofibroma
Types I and III collagens and the activities of prolyl hydroxylase and galactosylhydroxylysyl glucosyltransferase in skin lesions of tuberous sclerosis.
Arteriosclerosis
Aortic prolyl hydroxylase and the development of arteriosclerosis in the female breeder rat.
Increased collagen synthesis and the kinetic characteristics of prolyl hydroxylase in tissues of rabbits with experimental arteriosclerosis.
Arthritis, Experimental
Increased serum immunoreactive prolyl hydroxylase in rats with carrageenan-induced granuloma and adjuvant arthritis.
Levels of collagenolytic activity, beta-glucuronidase, and collagen prolyl hydroxylase in paws from rats with developing adjuvant arthritis.
Atherosclerosis
Deficiency of the oxygen sensor prolyl hydroxylase 1 attenuates hypercholesterolaemia, atherosclerosis, and hyperglycaemia.
Prolyl hydroxylase 3 overexpression accelerates the progression of atherosclerosis in ApoE-/- mice.
Biliary Atresia
Hepatic peptidyl prolyl hydroxylase activity and liver fibrosis--a prospective study of 94 infants and children with hepatobiliary disorders.
Bone Diseases, Developmental
Prolyl 3-Hydroxylase 1 and CRTAP are Mutually Stabilizing in the Endoplasmic Reticulum Collagen Prolyl 3-Hydroxylation Complex.
Substitution of murine type I collagen A1 3-hydroxylation site alters matrix structure but does not recapitulate osteogenesis imperfecta bone dysplasia.
Brain Injuries
Relative Contribution of Prolyl Hydroxylase-Dependent and -Independent Degradation of HIF-1alpha by Proteasomal Pathways in Cerebral Ischemia.
Brain Injuries, Traumatic
Prolyl hydroxylase regulates axonal rewiring and motor recovery after traumatic brain injury.
Brain Ischemia
Relative Contribution of Prolyl Hydroxylase-Dependent and -Independent Degradation of HIF-1alpha by Proteasomal Pathways in Cerebral Ischemia.
Breast Neoplasms
Collagen Prolyl Hydroxylases are Essential for Breast Cancer Metastasis.
Enzymes of collagen synthesis and type III procollagen amino-propeptide in serum from Nigerians with hepato-cellular carcinoma and other malignant diseases.
Immunoreactive prolyl hydroxylase protein and galactosylhydroxylysyl glucosyltransferase activity in breast tissues and sera of patients with primary breast cancer.
Inappropriate production of collagen and prolyl hydroxylase by human breast cancer cells in vivo.
Prolyl hydroxylase substrate adenylosuccinate lyase is an oncogenic driver in triple negative breast cancer.
The key hypoxia regulated gene CAIX is upregulated in basal-like breast tumours and is associated with resistance to chemotherapy.
The prolyl hydroxylase enzymes are positively associated with hypoxia-inducible factor-1? and vascular endothelial growth factor in human breast cancer and alter in response to primary systemic treatment with epirubicin and tamoxifen.
Burkitt Lymphoma
Enzymes of collagen synthesis and type III procollagen amino-propeptide in serum from Nigerians with hepato-cellular carcinoma and other malignant diseases.
Hypoxia-inducible factor-1? plays roles in Epstein-Barr virus's natural life cycle and tumorigenesis by inducing lytic infection through direct binding to the immediate-early BZLF1 gene promoter.
Carcinogenesis
A zebrafish model to study and therapeutically manipulate hypoxia signaling in tumorigenesis.
An insertion/deletion polymorphism within RERT-lncRNA modulates hepatocellular carcinoma risk.
Control of cyclin D1 and breast tumorigenesis by the EglN2 prolyl hydroxylase.
Edging toward new therapeutics with cyclin D1 Egl'ng on cancer.
EglN2 associates with the NRF1-PGC1? complex and controls mitochondrial function in breast cancer.
EglN2 positively regulates mitochondrial function in breast cancer.
Pheochromocytoma and paraganglioma.
Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase.
Carcinoma
Curcumin provides potential protection against the activation of hypoxia and prolyl 4-hydroxylase inhibitors on prostate-specific antigen expression in human prostate carcinoma cells.
Decreased prolyl hydroxylase 3 mRNA expression in oncocytomas compared with clear cell renal cell carcinoma.
Differential expression of MAP3K7 and TROPONIN C proteins and related perturbations in renal amyloidosis.
Hypoxia inducible prolyl hydroxylase PHD3 maintains carcinoma cell growth by decreasing the stability of p27.
Hypoxia-inducible factor-1? induces ErbB4 signaling in the differentiating mammary gland.
Hypoxia-inducible factor-1? plays roles in Epstein-Barr virus's natural life cycle and tumorigenesis by inducing lytic infection through direct binding to the immediate-early BZLF1 gene promoter.
mRNA overexpression of prolyl hydroxylase PHD3 is inversely related to nuclear grade in renal cell carcinoma.
PHD-2 activation: a novel strategy to control HIF-1? and mitochondrial stress to modulate mammary gland pathophysiology in ER+ subtype.
Prolyl hydroxylase 2 dependent and Von-HippelLindau independent degradation of Hypoxiainducible factor 1 and 2 alpha by selenium in clear cell renal cell carcinoma leads to tumor growth inhibition.
Prolyl hydroxylase mediated inhibition of fatty acid synthase to combat tumor growth in mammary gland carcinoma.
Prolyl hydroxylase PHD3 enhances the hypoxic survival and G1 to S transition of carcinoma cells.
Reduced expression of PHD2 prolyl hydroxylase gene in primary advanced uterine cervical carcinoma.
Retention of prolyl hydroxylase PHD2 in the cytoplasm prevents PHD2-induced anchorage-independent carcinoma cell growth.
VHL promotes immune response against renal cell carcinoma via NF-?B-dependent regulation of VCAM-1.
ZNF750 inhibited the malignant progression of oral squamous cell carcinoma by regulating tumor vascular microenvironment.
Carcinoma, Hepatocellular
Elevation of prolyl hydroxylase activity in Reuber hepatomas.
Enzymes of collagen synthesis and type III procollagen amino-propeptide in serum from Nigerians with hepato-cellular carcinoma and other malignant diseases.
LEPREL1 Expression in Human Hepatocellular Carcinoma and Its Suppressor Role on Cell Proliferation.
Liver immunoreactive prolyl hydroxylase protein in human primary hepatocellular carcinoma.
Prolyl hydroxylase-2 inhibits liver tumor cell proliferation and cyclin D1 expression in a hydroxylase-dependent manner.
Serum lysyl oxidase activity in chronic liver disease in comparison with serum levels of prolyl hydroxylase and laminin.
[Serum and tissue prolyl hydroxylase (PH) in hepatocellular carcinoma and gastrointestinal cancer]
Carcinoma, Renal Cell
Decreased prolyl hydroxylase 3 mRNA expression in oncocytomas compared with clear cell renal cell carcinoma.
iTRAQ proteomic identification of pVHL-dependent and -independent targets of Egln1 prolyl hydroxylase knockdown in renal carcinoma cells.
mRNA overexpression of prolyl hydroxylase PHD3 is inversely related to nuclear grade in renal cell carcinoma.
Prolyl hydroxylase 2 dependent and Von-HippelLindau independent degradation of Hypoxiainducible factor 1 and 2 alpha by selenium in clear cell renal cell carcinoma leads to tumor growth inhibition.
VHL promotes immune response against renal cell carcinoma via NF-?B-dependent regulation of VCAM-1.
Carcinoma, Squamous Cell
Differential expression of MAP3K7 and TROPONIN C proteins and related perturbations in renal amyloidosis.
Cardiomegaly
Collagen metabolism in experimental cardiac hypertrophy in the rat and the effect of digitoxin treatment.
Effects of long-term verapamil treatment on blood pressure, cardiac hypertrophy and collagen metabolism in spontaneously hypertensive rats.
Cardiovascular Diseases
Inhibition of prolyl hydroxylase domain-containing protein on hypertension/renal injury induced by high salt diet and nitric oxide withdrawal.
Cataract
Homozygous loss-of-function mutation of the LEPREL1 gene causes severe non-syndromic high myopia with early-onset cataract.
Cholestasis
Human prolyl hydroxylase. Purification, radioimmunoassay and clinical studies in liver diseases.
Chronic Limb-Threatening Ischemia
Prolyl hydroxylase domain-2 silencing induced by hydrodynamic limb vein injection enhances vascular regeneration in critical limb ischemia mice through activation of multiple genes.
Colitis
Contribution of epithelial innate immunity to systemic protection afforded by prolyl hydroxylase inhibition in murine colitis.
Differential expression of prolyl hydroxylase 1 in patients with ulcerative colitis versus patients with Crohn's disease/infectious colitis and healthy controls.
Oral Delivery of Prolyl Hydroxylase Inhibitor: AKB-4924 Promotes Localized Mucosal Healing in a Mouse Model of Colitis.
Colitis, Ulcerative
Differential expression of prolyl hydroxylase 1 in patients with ulcerative colitis versus patients with Crohn's disease/infectious colitis and healthy controls.
Prolyl hydroxylase activity in serum and rectal mucosa in inflammatory bowel disease.
Collagen Diseases
Prolyl hydroxylase and procollagen III peptide levels in the sera from patients with collagen diseases and psoriasis.
Colonic Neoplasms
Expression of delta-like ligand 4 (Dll4) and markers of hypoxia in colon cancer.
Colorectal Neoplasms
Low expression of prolyl hydroxylase 2 is associated with tumor grade and poor prognosis in patients with colorectal cancer.
Prolyl hydroxylase 3 attenuates MCL-1-mediated ATP production to suppress the metastatic potential of colorectal cancer cells.
Communicable Diseases
Three serum markers of collagen biosynthesis in Nigerians with cirrhosis and various infectious diseases.
Congenital Abnormalities
Bulbous epiphysis and popcorn calcification as related to growth plate differentiation in osteogenesis imperfecta.
Connective Tissue Diseases
Enzymes of collagen biosynthesis in skin and serum and dermatological diseases. II. Serum enzymes.
Enzymes of collagen biosynthesis in skin and serum in dermatological diseases. I. Enzymes of the skin.
Crohn Disease
Prolyl hydroxylase activity in serum and rectal mucosa in inflammatory bowel disease.
Cysts
Hypoxia-inducible factor-1? causes renal cyst expansion through calcium-activated chloride secretion.
Dermatomyositis
Enzymes of collagen biosynthesis in skin and serum and dermatological diseases. II. Serum enzymes.
Diabetic Angiopathies
[Clinical significance of serum prolyl hydroxylase in diabetic microangiopathy]
Diabetic Cardiomyopathies
Inhibition of prolyl hydroxylase 3 ameliorates cardiac dysfunction in diabetic cardiomyopathy.
Digestive System Diseases
Hepatic peptidyl prolyl hydroxylase activity and liver fibrosis--a prospective study of 94 infants and children with hepatobiliary disorders.
Ehlers-Danlos Syndrome
Genotyping and prenatal assessment of collagen lysyl hydroxylase deficiency in a family with Ehlers-Danlos syndrome type VI.
Osteogenesis imperfecta: Novel genetic variants and clinical observations from a clinical exome study of 54 Indian patients.
Enterocolitis, Necrotizing
Prolyl hydroxylase 2 silencing enhances the paracrine effects of mesenchymal stem cells on necrotizing enterocolitis in an NF-?B-dependent mechanism.
Escherichia coli Infections
Acidosis induces antimicrobial peptide expression and resistance to uropathogenic E. coli infection in kidney collecting duct cells via HIF-1?.
Fetal Growth Retardation
Reduced placental prolyl hydroxylase 3 mRNA expression in pregnancies affected by fetal growth restriction.
Gastrointestinal Neoplasms
[Serum and tissue prolyl hydroxylase (PH) in hepatocellular carcinoma and gastrointestinal cancer]
Glomerulonephritis
Nitric oxide mediates prolyl hydroxylase 3 expression in mesangial cells and in glomerulonephritis.
Glycogen Storage Disease
Hepatic peptidyl prolyl hydroxylase activity and liver fibrosis--a prospective study of 94 infants and children with hepatobiliary disorders.
Granuloma
Collagen prolyl hydroxylase inhibitor and reduced collagen formation in cotton pellet-induced granuloma and skin wound healing in rats.
Increased serum immunoreactive prolyl hydroxylase in rats with carrageenan-induced granuloma and adjuvant arthritis.
Inhibitory effects of glucocorticoids on collagen synthesis by mouse sponge granulomas and granuloma fibroblasts in culture.
Temporal response of prolyl hydroxylase in pre-existing granuloma to glucocorticoid administration.
Vitamin A prevention of triamcinolone acetonide effects on granuloma growth: lack of effect on prolyl hydroxylase.
[Parameters of collagen biosynthesis in cotton pellet granuloma of rats on iron deficiency (author's transl)]
[Peptidyl prolyl hydroxylase activity in relation to the actual collagen biosynthesis in cotton pellet granuloma of guinea pig (author's transl)]
Hearing Loss
Prolyl 3-hydroxylase-1 null mice exhibit hearing impairment and abnormal morphology of the middle ear bone joints.
Heart Failure
Discovery of a murine model of clinical PAH: Mission impossible?
Somatic inactivation of the PHD2 prolyl hydroxylase causes polycythemia and congestive heart failure.
Hepatitis
Clinical significance of serum 7S collagen in various liver diseases.
Hepatic peptidyl prolyl hydroxylase activity and liver fibrosis--a prospective study of 94 infants and children with hepatobiliary disorders.
Liver immunoreactive prolyl hydroxylase protein in human primary hepatocellular carcinoma.
Modifications in the serum concentrations of prolyl hydroxylase in patients with chronic hepatitis B during and after interferon therapy.
Prolyl hydroxylase activity in normal and diseased human liver.
Serum immunoreactive prolyl hydroxylase in liver disease.
Serum lysyl oxidase activity in chronic liver disease in comparison with serum levels of prolyl hydroxylase and laminin.
[Hepatic fibrosis and its serum markers]
Hepatitis B, Chronic
Modifications in the serum concentrations of prolyl hydroxylase in patients with chronic hepatitis B during and after interferon therapy.
Hepatitis, Alcoholic
Prolyl hydroxylase activity in normal and diseased human liver.
Hepatitis, Chronic
Hepatic peptidyl prolyl hydroxylase activity and liver fibrosis--a prospective study of 94 infants and children with hepatobiliary disorders.
Serum immunoreactive prolyl hydroxylase in liver disease.
Serum lysyl oxidase activity in chronic liver disease in comparison with serum levels of prolyl hydroxylase and laminin.
Hypertension
Aorta collagen metabolism in spontaneously hypertensive and aortic-constricted rats: variations in enzyme activities concerned with disaccharide unit synthesis and degradation according to blood pressure and age.
DMOG, a Prolyl Hydroxylase Inhibitor, Increases Hemoglobin Levels without Exacerbating Hypertension and Renal Injury in Salt-Sensitive Hypertensive Rats.
Effects of prolyl hydroxylase inhibition on arterial collagen synthesis and blood pressure in hypertensive rats.
Exercise training attenuates placental ischemia-induced hypertension and angiogenic imbalance in the rat.
Increased prolyl hydroxylase activity in the aorta and heart in rat after induction of acute hypertension.
Hypertension, Pulmonary
Differential and reciprocal regulation between hypoxia-inducible factor-alpha subunits and their prolyl hydroxylases in pulmonary arteries of rat with hypoxia-induced hypertension.
Infarction, Middle Cerebral Artery
Relative Contribution of Prolyl Hydroxylase-Dependent and -Independent Degradation of HIF-1alpha by Proteasomal Pathways in Cerebral Ischemia.
Infections
Acidosis induces antimicrobial peptide expression and resistance to uropathogenic E. coli infection in kidney collecting duct cells via HIF-1?.
Liver procollagen prolyl hydroxylase in Opisthorchis viverrini infected hamsters after praziquantel administration.
PHD2 exerts anti-cancer and anti-inflammatory effects in colon cancer xenografts mice via attenuating NF-?B activity.
Serum and liver enzymes of collagen synthesis in hepatic murine schistosomiasis mansoni.
Toxoplasma gondii activates hypoxia-inducible factor (HIF) by stabilizing the HIF-1alpha subunit via type I activin-like receptor kinase receptor signaling.
Inflammatory Bowel Diseases
Loss of Prolyl Hydroxylase-1 Protects Against Colitis Through Reduced Epithelial Cell Apoptosis and Increased Barrier Function.
Prolyl hydroxylase activity in serum and rectal mucosa in inflammatory bowel disease.
Iron Deficiencies
Prolyl hydroxylase inhibition corrects functional iron deficiency and inflammation-induced anaemia in rats.
Iron Overload
[Course of the prolyl hydroxylase activity and the quantity of collagen amino acids in the liver during a 2-year experimental chronic iron overload in baboons]
Irritable Bowel Syndrome
Prolyl hydroxylase activity in serum and rectal mucosa in inflammatory bowel disease.
Keloid
Biochemical composition of the connective tissue in keloids and analysis of collagen metabolism in keloid fibroblast cultures.
Collagen prolyl hydroxylase inhibitor and reduced collagen formation in cotton pellet-induced granuloma and skin wound healing in rats.
Enzymes of collagen biosynthesis in skin and serum in dermatological diseases. I. Enzymes of the skin.
Reduction of collagen production in keloid fibroblast cultures by ethyl-3,4-dihydroxybenzoate. Inhibition of prolyl hydroxylase activity as a mechanism of action.
Variation in prolyl hydroxylase activity of keloid-derived and normal human fibroblasts in response to hydrocortisone and ascorbic acid.
Ketosis
Neuroprotection in diet-induced ketotic rat brain after focal ischemia.
Kidney Diseases
Hypoxia signaling in renal pericytes-is it safe to activate?
Kidney Failure, Chronic
Differential expression of MAP3K7 and TROPONIN C proteins and related perturbations in renal amyloidosis.
Influence of acute and chronic kidney failure in rats on the disposition and pharmacokinetics of ZYAN1, a novel prolyl hydroxylase inhibitor, for the treatment of chronic kidney disease-induced anemia.
Kidney Neoplasms
Emetine promotes VHL-independent degradation of hypoxia inducible factor-2{alpha} in clear cell renal carcinoma.
Prolyl Hydroxylase 3 Knockdown Accelerates VHL-Mutant Kidney Cancer Growth In Vivo.
Leiomyoma
Human prolyl hydroxylase expression in uterine leiomyoma during the menstrual cycle.
Lens Subluxation
Recessive Mutations in LEPREL1 Underlie a Recognizable Lens Subluxation Phenotype.
Lichen Planus
Enzymes of collagen biosynthesis in skin and serum in dermatological diseases. I. Enzymes of the skin.
Liver Cirrhosis
Beneficial effect of a traditional herbal medicine (inchin-ko-to) in postoperative biliary atresia patients.
Collagen production in fat-storing cells after carbon tetrachloride intoxication in the rat. Immunoelectron microscopic observation of type I, type III collagens, and prolyl hydroxylase.
Fibrogenic and collagenolytic activity in carbon-tetrachloride-injured rats: beneficial effects of zinc administration.
Liver collagen hydroxylation in murine schistosomiasis.
Methotrexate therapy and liver fibrosis: are human prolyl hydroxylase and type IV collagen reliable and sensitive markers?
Prolyl hydroxylase activity as an index of liver damage induced by ethanol.
Prolyl hydroxylase activity in liver and serum of rats and human subjects intoxicated by chronic administration of ethanol.
Serum lysyl oxidase activity in chronic liver disease in comparison with serum levels of prolyl hydroxylase and laminin.
Serum markers for fibrosis and plasma transforming growth factor-beta 1 in patients with hepatocellular carcinoma in comparison with patients with liver cirrhosis.
[A histological examination of liver fibrosis and tissue prolyl hydroxylase in various liver diseases]
[Recent advances in laboratory tests for liver diseases]
Liver Cirrhosis, Biliary
Enzymes of collagen synthesis and type III procollagen aminopropeptide in the evaluation of D-penicillamine and medroxyprogesterone treatments of primary biliary cirrhosis.
Serum immunoreactive prolyl hydroxylase in liver disease.
Liver Diseases
A comparison of four serum markers of fibrosis in the diagnosis of cirrhosis.
Are serum type III procollagen and prolyl hydroxylase useful as noninvasive markers of liver disease in patients with cystic fibrosis?
Collagen biosynthesis enzymes in serum and hepatic tissue in liver disease. I. Prolyl hydroxylase.
Extracellular matrix formation in piecemeal necrosis: immunoelectron microscopic study.
Hepatic prolyl hydroxylase activity in human liver disease.
Human prolyl hydroxylase. Purification, radioimmunoassay and clinical studies in liver diseases.
Serum immunoreactive prolyl hydroxylase in liver disease.
Serum lysyl oxidase activity in chronic liver disease in comparison with serum levels of prolyl hydroxylase and laminin.
Serum type III procollagen peptide as a non-invasive marker of liver damage during infancy and childhood in extrahepatic biliary atresia, idiopathic hepatitis of infancy and alpha 1 antitrypsin deficiency.
[A histological examination of liver fibrosis and tissue prolyl hydroxylase in various liver diseases]
[Prolyl hydroxylase activity and collagenase activity in the liver tissue of non-alcoholic chronic liver diseases]
[Prolyl hydroxylase activity in liver specimens in chronic liver diseases (author's transl)]
[Serum prolyl hydroxylase values in liver diseases]
Liver Diseases, Alcoholic
Hepatic prolyl hydroxylase and collagen synthesis in patients with alcoholic liver disease.
Liver Neoplasms
Enzymes of collagen synthesis and type III procollagen amino-propeptide in serum from Nigerians with hepato-cellular carcinoma and other malignant diseases.
Prolyl hydroxylase-2 inhibits liver tumor cell proliferation and cyclin D1 expression in a hydroxylase-dependent manner.
Serum prolyl hydroxylase protein in experimental liver cancer.
Lung Injury
Inhibition of Prolyl Hydroxylase Attenuates Fas Ligand-induced Apoptosis and Lung Injury in Mice.
The influence of proline analogs on bleomycin-induced lung injury in rats.
Lung Neoplasms
Collagen prolyl hydroxylase 3 has a tumor suppressive activity in human lung cancer.
Fine Mapping in Chromosome 3q28 Identified Two Variants Associated with Lung Cancer Risk in Asian Population.
Prolyl hydroxylase 3 involvement in lung cancer progression under hypoxic conditions: association with hypoxia-inducible factor-1? and pyruvate kinase M2.
Lupus Erythematosus, Systemic
Enzymes of collagen biosynthesis in skin and serum and dermatological diseases. II. Serum enzymes.
Lymphoma
HIF-dependent antitumorigenic effect of antioxidants in vivo.
Reactivation of Epstein-Barr Virus by HIF-1? Requires p53.
Lymphoma, B-Cell
The effects of doxycycline and micronized purified flavonoid fraction on human vein wall remodeling are not hypoxia-inducible factor pathway-dependent.
Malnutrition
Aberrant expression of hypoxia-inducible factor 1? in the fetal heart is associated with maternal undernutrition.
Melanoma
Collagen Prolyl Hydroxylases Are Bifunctional Growth Regulators in Melanoma.
Hypoxia-induced transcriptional repression of the melanoma-associated oncogene MITF.
Vernonia cinerea Less. Inhibits Tumor Cell Invasion and Pulmonary Metastasis in C57BL/6 Mice.
Myelodysplastic Syndromes
Roxadustat: First Global Approval.
Myocardial Infarction
Double knockdown of prolyl hydroxylase and factor-inhibiting hypoxia-inducible factor with nonviral minicircle gene therapy enhances stem cell mobilization and angiogenesis after myocardial infarction.
Effects of a prolyl hydroxylase inhibitor on kidney and cardiovascular complications in a rat model of chronic kidney disease.
Targeted Gene deletion of Prolyl Hydroxylase Domain Protein 3 Triggers Angiogenesis And Preserves Cardiac Function by stabilizing Hypoxia inducible Factor 1 Alpha Following Myocardial Infarction.
Myopia
Detection of mutations in LRPAP1, CTSH, LEPREL1, ZNF644, SLC39A5, and SCO2 in 298 families with early-onset high myopia by exome sequencing.
High myopia caused by a mutation in LEPREL1, encoding prolyl 3-hydroxylase 2.
Homozygous loss-of-function mutation of the LEPREL1 gene causes severe non-syndromic high myopia with early-onset cataract.
Mutational screening of SLC39A5, LEPREL1 and LRPAP1 in a cohort of 187 high myopia patients.
Post-translationally abnormal collagens of prolyl 3-hydroxylase-2 null mice offer a pathobiological mechanism for the high myopia linked to human LEPREL1 mutations*
Neoplasm Metastasis
A hidden aggregation-prone structure in the heart of hypoxia inducible factor prolyl hydroxylase.
Amentoflavone Inhibits Experimental Tumor Metastasis Through a Regulatory Mechanism Involving MMP-2, MMP-9, Prolyl Hydroxylase, Lysyl Oxidase, VEGF, ERK-1, ERK-2, STAT-1, nm23 and Cytokines in Lung Tissues of C57BL/6 Mice.
Biophytum sensitivum (L.) DC inhibits tumor cell invasion and metastasis through a mechanism involving regulation of MMPs, prolyl hydroxylase, lysyl oxidase, nm23, ERK-1, ERK-2, STAT-1, and proinflammatory cytokine gene expression in metastatic lung tissue.
Collagen Prolyl Hydroxylases are Essential for Breast Cancer Metastasis.
Prolyl hydroxylase and hypoxia inducible factor: potential targets for cancer therapy.
Neoplasms
"S'ils n'ont pas de pain, qu'ils mangent de la brioche." Focus on "anaerobic respiration sustains mitochondrial membrane potential in a prolyl hydroxylase pathway-activated cancer cell line in a hypoxic microenvironment".
A hidden aggregation-prone structure in the heart of hypoxia inducible factor prolyl hydroxylase.
Activation of hypoxia-inducible factor-1 via prolyl-4 hydoxylase-2 gene silencing attenuates acute inflammatory responses in postischemic myocardium.
Amentoflavone Inhibits Experimental Tumor Metastasis Through a Regulatory Mechanism Involving MMP-2, MMP-9, Prolyl Hydroxylase, Lysyl Oxidase, VEGF, ERK-1, ERK-2, STAT-1, nm23 and Cytokines in Lung Tissues of C57BL/6 Mice.
Anaerobic respiration sustains mitochondrial membrane potential in prolyl hydroxylase pathway-activated cancer cell line in a hypoxic microenvironment.
Biophytum sensitivum (L.) DC inhibits tumor cell invasion and metastasis through a mechanism involving regulation of MMPs, prolyl hydroxylase, lysyl oxidase, nm23, ERK-1, ERK-2, STAT-1, and proinflammatory cytokine gene expression in metastatic lung tissue.
C-Terminal HSP90 Inhibitors Block the HIF-1 Hypoxic Response by Degrading HIF-1? through the Oxygen-Dependent Degradation Pathway.
Collagen prolyl hydroxylase 3 has a tumor suppressive activity in human lung cancer.
Collagen Prolyl Hydroxylases Are Bifunctional Growth Regulators in Melanoma.
Collagen Prolyl Hydroxylases are Essential for Breast Cancer Metastasis.
Controlling the Phenotype of Tumor-Infiltrating Macrophages via the PHD-HIF Axis Inhibits Tumor Growth in a Mouse Model.
Depletion of ascorbic acid restricts angiogenesis and retards tumor growth in a mouse model.
Docetaxel induced-JNK2/PHD1 signaling pathway increases degradation of HIF-1? and causes cancer cell death under hypoxia.
Edging toward new therapeutics with cyclin D1 Egl'ng on cancer.
Effect of prolyl hydroxylase domain-2 haplodeficiency on the hepatocarcinogenesis in mice.
Endothelial cell metabolism and tumour angiogenesis: glucose and glutamine as essential fuels and lactate as the driving force.
Enzymes of collagen synthesis and type III procollagen amino-propeptide in serum from Nigerians with hepato-cellular carcinoma and other malignant diseases.
Estrogen receptor ? sustains epithelial differentiation by regulating prolyl hydroxylase 2 transcription.
Fine Mapping in Chromosome 3q28 Identified Two Variants Associated with Lung Cancer Risk in Asian Population.
Function and expression of prolyl hydroxylase 3 in cancers.
Inappropriate production of collagen and prolyl hydroxylase by human breast cancer cells in vivo.
Insulin/IGF-1 and Hypoxia Signaling Act in Concert to Regulate Iron Homeostasis in Caenorhabditis elegans.
Knockout of mitochondrial thioredoxin reductase stabilizes prolyl hydroxylase 2 and inhibits tumor growth and tumor-derived angiogenesis.
LEPREL1 Expression in Human Hepatocellular Carcinoma and Its Suppressor Role on Cell Proliferation.
Loss of PHD3 allows tumours to overcome hypoxic growth inhibition and sustain proliferation through EGFR.
Low expression of prolyl hydroxylase 2 is associated with tumor grade and poor prognosis in patients with colorectal cancer.
mRNA overexpression of prolyl hydroxylase PHD3 is inversely related to nuclear grade in renal cell carcinoma.
Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: developmental culling and cancer.
P3H4 is correlated with clinicopathological features and prognosis in bladder cancer.
PHD-2 activation: a novel strategy to control HIF-1? and mitochondrial stress to modulate mammary gland pathophysiology in ER+ subtype.
PHD3 affects gastric cancer progression by negatively regulating HIF1A.
PHD3 regulates EGFR internalization and signalling in tumours.
Prolyl hydroxylase 2 dependent and Von-HippelLindau independent degradation of Hypoxiainducible factor 1 and 2 alpha by selenium in clear cell renal cell carcinoma leads to tumor growth inhibition.
Prolyl hydroxylase 2: a promising target to inhibit hypoxia-induced cellular metabolism in cancer cells.
Prolyl hydroxylase 3 involvement in lung cancer progression under hypoxic conditions: association with hypoxia-inducible factor-1? and pyruvate kinase M2.
Prolyl hydroxylase 3 stabilizes the p53 tumor suppressor by inhibiting the p53-MDM2 interaction in a hydroxylase-independent manner.
Prolyl hydroxylase and hypoxia inducible factor: potential targets for cancer therapy.
Prolyl Hydroxylase Inhibition Enhances Liver Regeneration Without Induction of Tumor Growth.
Prolyl hydroxylase inhibitor dimethyloxalylglycine enhances mesenchymal stem cell survival.
Prolyl hydroxylase mediated inhibition of fatty acid synthase to combat tumor growth in mammary gland carcinoma.
Prolyl hydroxylase-2 inhibits liver tumor cell proliferation and cyclin D1 expression in a hydroxylase-dependent manner.
Reactive oxygen species attenuate nitric-oxide-mediated hypoxia-inducible factor-1alpha stabilization.
Regulation of HIF prolyl hydroxylases by hypoxia-inducible factors.
Regulation of IL-1?-induced NF-?B by hydroxylases links key hypoxic and inflammatory signaling pathways.
Serum markers for fibrosis and plasma transforming growth factor-beta 1 in patients with hepatocellular carcinoma in comparison with patients with liver cirrhosis.
The key hypoxia regulated gene CAIX is upregulated in basal-like breast tumours and is associated with resistance to chemotherapy.
The prolyl hydroxylase enzymes are positively associated with hypoxia-inducible factor-1? and vascular endothelial growth factor in human breast cancer and alter in response to primary systemic treatment with epirubicin and tamoxifen.
Tumour blood vessel normalisation by prolyl hydroxylase inhibitor repaired sensitivity to chemotherapy in a tumour mouse model.
Types I and III collagens and the activities of prolyl hydroxylase and galactosylhydroxylysyl glucosyltransferase in skin lesions of tuberous sclerosis.
Validation of a hypoxia-inducible factor-1 alpha specimen collection procedure and quantitative enzyme-linked immunosorbent assay in solid tumor tissues.
Wogonin inhibits tumor angiogenesis via degradation of HIF-1? protein.
ZNF750 inhibited the malignant progression of oral squamous cell carcinoma by regulating tumor vascular microenvironment.
[The effect of PHD inhibitor on tumor microenvironment and tumor immune response].
[Type III procollagen N-terminal peptide (P-III-P, prolyl hydroxylase (PH), and laminin P1 levels in serum and BALF of radiotherapy patients]
Nephritis, Interstitial
Mononuclear phagocytes orchestrate prolyl hydroxylase inhibition-mediated renoprotection in chronic tubulointerstitial nephritis.
Neuroinflammatory Diseases
HIF-1? stabilization reduces retinal degeneration in a mouse model of retinitis pigmentosa.
Obesity
Prolyl Hydroxylase Domain-2 Inhibition Improves Skeletal Muscle Regeneration in a Male Murine Model of Obesity.
Osteogenesis Imperfecta
A founder mutation in LEPRE1 carried by 1.5% of West Africans and 0.4% of African Americans causes lethal recessive osteogenesis imperfecta.
A moderate form of osteogenesis imperfecta caused by compound heterozygous LEPRE1 mutations.
A novel mutation in LEPRE1 that eliminates only the KDEL ER- retrieval sequence causes non-lethal osteogenesis imperfecta.
Allelic background of LEPRE1 mutations that cause recessive forms of osteogenesis imperfecta in different populations.
Bone matrix hypermineralization in prolyl-3 hydroxylase 1 deficient mice.
CRTAP and LEPRE1 mutations in recessive osteogenesis imperfecta.
Crtap and p3h1 knock out zebrafish support defective collagen chaperoning as the cause of their osteogenesis imperfecta phenotype.
CRTAP mutations in lethal and severe osteogenesis imperfecta: the importance of combining biochemical and molecular genetic analysis.
Differential effects of collagen prolyl 3-hydroxylation on skeletal tissues.
Expression of prolyl 3-hydroxylase genes in embryonic and adult mouse tissues.
Generalized connective tissue disease in Crtap-/- mouse.
Genetics of bone diseases: Paget's disease, fibrous dysplasia, osteopetrosis, and osteogenesis imperfecta.
Lack of cyclophilin B in osteogenesis imperfecta with normal collagen folding.
Lethal/ Severe Osteogenesis Imperfecta in a Large Family: A Novel Homozygous LEPRE1 Mutation and Bone Histological Findings.
Non-Lethal Type VIII Osteogenesis Imperfecta Has Elevated Bone Matrix Mineralization.
Novel Deletion of SERPINF1 Causes Autosomal Recessive Osteogenesis Imperfecta Type VI in Two Brazilian Families.
Null mutations in LEPRE1 and CRTAP cause severe recessive osteogenesis imperfecta.
Osteogenesis imperfecta caused by COL1A1, CRTAP and LEPRE1 mutations. Report of 2cases.
Osteogenesis imperfecta due to compound heterozygosity for the LEPRE1 gene.
Osteogenesis imperfecta: questions and answers.
Osteogenesis imperfecta: recent findings shed new light on this once well-understood condition.
PPIB mutations cause severe osteogenesis imperfecta.
Prolyl 3-Hydroxylase 1 and CRTAP are Mutually Stabilizing in the Endoplasmic Reticulum Collagen Prolyl 3-Hydroxylation Complex.
Prolyl 3-hydroxylase 1 deficiency causes a recessive metabolic bone disorder resembling lethal/severe osteogenesis imperfecta.
Prolyl 3-hydroxylase-1 null mice exhibit hearing impairment and abnormal morphology of the middle ear bone joints.
Recessive osteogenesis imperfecta caused by LEPRE1 mutations: clinical documentation and identification of the splice form responsible for prolyl 3-hydroxylation.
Sc65 is a novel endoplasmic reticulum protein that regulates bone mass homeostasis.
Substitution of murine type I collagen A1 3-hydroxylation site alters matrix structure but does not recapitulate osteogenesis imperfecta bone dysplasia.
The identification of novel mutations in COL1A1, COL1A2, and LEPRE1 genes in Chinese patients with osteogenesis imperfecta.
Osteoporosis
A novel mutation in collagen gene COL1A2 associated with transient regional osteoporosis.
Osteosarcoma
Role of reactive oxygen species in the regulation of HIF-1 by prolyl hydroxylase 2 under mild hypoxia.
Upregulated LEPRE1 correlates with poor outcome and its knockdown attenuates cells proliferation, migration and invasion in osteosarcoma.
Ovarian Neoplasms
Genome-Wide Interrogation of Human Cancers Identifies EGLN1 Dependency in Clear Cell Ovarian Cancers.
Pancreatitis, Chronic
Prolyl hydroxylase and tissue inhibitor of metalloproteinase in pure pancreatic juice in patients with chronic pancreatitis.
Paraganglioma
A systematic review on the genetic analysis of paragangliomas: primarily focused on head and neck paragangliomas.
Parkinson Disease
A possible novel anti-inflammatory mechanism for the pharmacological prolyl hydroxylase inhibitor 3,4-dihydroxybenzoate: implications for use as a therapeutic for Parkinson's disease.
Inhibition of prolyl hydroxylase protects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity: model for the potential involvement of the hypoxia-inducible factor pathway in Parkinson disease.
Neuroprotection of deferoxamine on rotenone-induced injury via accumulation of HIF-1 alpha and induction of autophagy in SH-SY5Y cells.
Pheochromocytoma
Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: developmental culling and cancer.
Pneumonia
PHD2 exerts anti-cancer and anti-inflammatory effects in colon cancer xenografts mice via attenuating NF-?B activity.
Polycythemia
A phenotypic perspective on Mammalian oxygen sensor candidates.
Computational analysis of prolyl hydroxylase domain-containing protein 2 (PHD2) mutations promoting polycythemia insurgence in humans.
Disturbance in the HIF-1alpha pathway associated with erythrocytosis: further evidences brought by frameshift and nonsense mutations in the prolyl hydroxylase domain protein 2 (PHD2) gene.
Isolated Erythrocytosis Associated With 3 Novel Missense Mutations in the EGLN1 Gene.
Somatic inactivation of the PHD2 prolyl hydroxylase causes polycythemia and congestive heart failure.
Pouchitis
Prolyl Hydroxylase Inhibition Mitigates Pouchitis.
Primary Myelofibrosis
Immunoreactive prolyl hydroxylase in patients with primary and secondary myelofibrosis.
procollagen-proline 3-dioxygenase deficiency
Prolyl 3-hydroxylase 1 deficiency causes a recessive metabolic bone disorder resembling lethal/severe osteogenesis imperfecta.
Prostatic Neoplasms
Methylseleninic acid downregulates hypoxia-inducible factor-1? in invasive prostate cancer.
Resveratrol integrates metabolic and growth effects in PC3 prostate cancer cells-involvement of prolyl hydroxylase and hypoxia inducible factor-1.
Psoriasis
Enzymes of collagen biosynthesis in skin and serum in dermatological diseases. I. Enzymes of the skin.
Prolyl hydroxylase and procollagen III peptide levels in the sera from patients with collagen diseases and psoriasis.
Pulmonary Fibrosis
A novel profibrotic mechanism mediated by TGF?-stimulated collagen prolyl hydroxylase expression in fibrotic lung mesenchymal cells.
Enzymes of collagen synthesis in lung tissues of bleomycin-induced pulmonary fibrosis.
Taurine and niacin offer a novel therapeutic modality in prevention of chemically-induced pulmonary fibrosis in hamsters.
[Type III procollagen N-terminal peptide (P-III-P, prolyl hydroxylase (PH), and laminin P1 levels in serum and BALF of radiotherapy patients]
Renal Insufficiency, Chronic
A Randomized, Placebo- and Positive-Controlled, Single-Dose, Crossover Thorough QT/QTc Study Assessing the Effect of Daprodustat on Cardiac Repolarization in Healthy Subjects.
Differential expression of MAP3K7 and TROPONIN C proteins and related perturbations in renal amyloidosis.
DMOG, a Prolyl Hydroxylase Inhibitor, Increases Hemoglobin Levels without Exacerbating Hypertension and Renal Injury in Salt-Sensitive Hypertensive Rats.
Effectiveness of hypoxia-induced factor prolyl hydroxylase inhibitor for managing anemia in chronic kidney disease: a systematic review and meta-analysis.
Effects of a prolyl hydroxylase inhibitor on kidney and cardiovascular complications in a rat model of chronic kidney disease.
HIF stabilization by prolyl hydroxylase inhibitors for the treatment of anemia in chronic kidney disease.
Influence of acute and chronic kidney failure in rats on the disposition and pharmacokinetics of ZYAN1, a novel prolyl hydroxylase inhibitor, for the treatment of chronic kidney disease-induced anemia.
Pharmacologic Targeting of Hypoxia-Inducible Factors.
Protein Hydroxylation by Hypoxia-Inducible Factor (HIF) Hydroxylases: Unique or Ubiquitous?
Roxadustat attenuates experimental pulmonary fibrosis in vitro and in vivo.
Roxadustat Markedly Reduces Myocardial Ischemia Reperfusion Injury in Mice.
Roxadustat: First Global Approval.
Study design and baseline characteristics of patients on dialysis in the ASCEND-D trial.
The oral hypoxia-inducible factor prolyl hydroxylase inhibitor enarodustat counteracts alterations in renal energy metabolism in the early stages of diabetic kidney disease.
Vadadustat: First Approval.
Whether Prolyl Hydroxylase Blocker-Roxadustat-In the Treatment of Anemia in Patients with Chronic Kidney Disease Is the Future?
Reperfusion Injury
Adaptation to moderate hypoxia protects cortical neurons against ischemia-reperfusion injury and excitotoxicity independently of HIF-1?.
Retinal Degeneration
HIF-1? stabilization reduces retinal degeneration in a mouse model of retinitis pigmentosa.
Retinal Perforations
Bilateral giant retinal tears in Osteogenesis Imperfecta.
Retinitis Pigmentosa
Oxygen-dependent diseases in the retina: role of hypoxia-inducible factors.
Rheumatic Diseases
Serum immunoreactive prolyl hydroxylase in inflammatory rheumatic diseases.
Rheumatoid Nodule
Palisading cells of rheumatoid nodules: comparison with synovial intimal cells.
Sarcoma
Regulation of collagen post-translational modification in transformed human and chick-embryo cells.
Sarcoma, Avian
Regulation of collagen post-translational modification in transformed human and chick-embryo cells.
Regulation of proline 3-hydroxylation and prolyl 3-hydroxylase and 4-hydroxylase activities in transformed cells.
Schistosomiasis
Liver collagen hydroxylation in murine schistosomiasis.
Scleroderma, Diffuse
Prolyl hydroxylase and procollagen III peptide levels in the sera from patients with collagen diseases and psoriasis.
Scurvy
Prolyl Hydroxylases and Therapeutics.
Skin Diseases
Enzymes of collagen biosynthesis in skin and serum in dermatological diseases. I. Enzymes of the skin.
Starvation
Targeting of the molecular chaperone oxygen-regulated protein 150 (ORP150) to mitochondria and its induction by cellular stress.
Stomach Neoplasms
Prolyl hydroxylase 3 inhibited the tumorigenecity of gastric cancer cells.
Reactivation of Epstein-Barr Virus by HIF-1? Requires p53.
Stroke
Bone Marrow Mononuclear Cells Transplantation and Training Increased Transplantation of Energy Source Transporters in Chronic Stroke.
Prophylactic neuroprotection against stroke: low-dose, prolonged treatment with deferoxamine or deferasirox establishes prolonged neuroprotection independent of HIF-1 function.
Translation of ischemic preconditioning to the patient: prolyl hydroxylase inhibition and hypoxia inducible factor-1 as novel targets for stroke therapy.
Tendinopathy
Genome-wide analysis identifies differential promoter methylation of Leprel2, Foxf1, Mmp25, Igfbp6, and Peg12 in murine tendinopathy.
Triple Negative Breast Neoplasms
Prolyl hydroxylase substrate adenylosuccinate lyase is an oncogenic driver in triple negative breast cancer.
Tuberous Sclerosis
Types I and III collagens and the activities of prolyl hydroxylase and galactosylhydroxylysyl glucosyltransferase in skin lesions of tuberous sclerosis.
Ureteral Obstruction
Effects of orally active hypoxia inducible factor alpha prolyl hydroxylase inhibitor, FG4592 on renal fibrogenic potential in mouse unilateral ureteral obstruction model.
Urinary Bladder Neoplasms
Identification of an enhancer region within the TP63/LEPREL1 locus containing genetic variants associated with bladder cancer risk.
Uterine Cervical Neoplasms
Apicidin upregulates PHD2 prolyl hydroxylase gene expression in cervical cancer cells.
Vitreous Detachment
Bilateral giant retinal tears in Osteogenesis Imperfecta.